$6.14 0.47 (+8.33%)
2/10/2012 4:00 PM

Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Featured Broker Partners


Advertisement